Alveo Technologies partners with CDC to develop rapid test for avian influenza in humans

Alveo Technologies has signed an agreement with the CDC to develop a rapid diagnostic test for detecting Influenza A, B, and H5 viruses in humans. This new test aims to improve public health preparedness amid concerns over avian influenza. The CDC's initiative follows a call for innovative diagnostic solutions, as current testing capabilities are limited to a few public health laboratories. Alveo's portable testing platform will allow for quicker, decentralized testing, reducing the burden on centralized labs. Alveo plans to start shipping a molecular test for avian influenza subtypes in poultry next month. This agreement aligns with Alveo's broader strategy to enhance global health and food security through accessible diagnostics.